Argenx Earnings Up In Q3

argenx ADR (ARGX) reported Q3 EPS of $7.80, missing estimates by $0.10, but revenue of $1.72B exceeded expectations of $1.65B. The stock closed at $890.05, down 3.07% over 3 months but up 9.59% year-over-year. InvestingPro rates its financial health as 'great performance'.

argenx (ARGX) reported Q3 2026 sales of $1.7B, up 54% YoY, with net profit of $506M. FDA granted priority review for VYVGART Hytrulo, with a PDUFA date set for February 2027. The company also announced positive Phase 3 results for VYVGART in IMNM and dermatomyositis, and plans to file an sBLA for IMNM by year-end. ARGX closed the Forte Biosciences deal, spending about $2.1B, and has cash of near $3.7B as of September 30, 2026.

Argenx SE reported Q3 2026 revenue of $1.75B, up from $1.15B a year ago, with net income of $506M. Nine-month revenue reached $4.61B, up from $2.93B, with net income of $1.34B. The company develops and commercializes antibody-based medicines for autoimmune diseases.

Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, treating generalized myasthenia gravis. Operating profit was $486M, below estimates. The company completed a $2.2B acquisition of Forte Biosciences, adding a drug for vitiligo and celiac disease. Operating margin declined to 28.2% due to acquisition costs, and R&D expenses are expected to reach $4B by 2026.

argenx SE (ARGX) reported Q3 2026 earnings per share of $7.80, up from $5.18 a year ago, with product sales growing 53% YoY to $1.72B. The company trades at $890.05, 44.3% below its GF Value of $1,597.83, indicating undervaluation. ARGX has a GF Score of 79, reflecting strong financial health and growth. Institutional investors show confidence, with eight gurus holding the stock.

Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, driven by expanded patient reach. Operating profit was $486M, missing estimates. The company completed a $2.2B acquisition of Forte Biosciences, impacting operating margins and increasing R&D costs to $4B for 2026.